TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hepatic Venous Pressure Gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SRSS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 180-day composite of death, transplant, or rehospitalization
Endpoint domain: Mortality/survival
Primary endpoint: serial creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: acquisition of basic suturing and knot tying skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak serum concentration of piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum serum concentration of piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clearance of piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG frequency spectrum shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appendicular Skeletal Muscle Mass (ASM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median offset time of the motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median offset time of the sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: size homogeneity of antral follicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of follicles reaching maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mFARS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Normalized movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDMS-2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WeeFIM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: anatomical cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 1-repetition maximum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: VAS pain scores at 6 h and 24 h after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSS score after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of infants alive and extubated at 14 days
Endpoint domain: Mortality/survival
Primary endpoint: length of mechanical ventilation in survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of infants alive without a supplemental oxygen requirement at 36 weeks' postmenstrual age
Endpoint domain: Mortality/survival
Primary endpoint: Verteporfin infusion‐associated pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoarthritic subchondral bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cartilage surface erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Systemic MF exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic formoterol exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 4-kg weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean duration of menstrual flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scanty periods and amenorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daytime nasal symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health-promoting lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Life Years (LYs)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk of Type 2 Diabetes (T2D)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence rate of major depression or anxiety disorder
Endpoint domain: Mortality/survival
Primary endpoint: Peak bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean amount of propofol infused per kilogram body weight and hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of the TCI system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias of the TCI system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ePOCD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage reduction in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median response to a mentoring request times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perceive and identify anatomical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for telementoring hardware platforms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rT₃ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: fT₄ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: average SpO2 (%) during the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total minute ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of IPVs on duplex imaging at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of shoulder dystocia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Non-inferiority of Ex-Reg to Regadenoson
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular morbidity or mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage reduction in MADRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients in total remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum voluntary muscle strength increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month gross cumulative expulsion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: removal rates due to bleeding and/or pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin changes of scleroderma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: eGFR trajectories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Protection against newly detected HPV31 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of sick-leave days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: remission of MDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ppFEV1 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IL-8 concentrations reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: upper limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Commission errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IIRTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative urinary problems (urinary symptoms or UTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total score of UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bonding strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow through the SFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: odor thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced intensity of skin tests to treatment allergens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disappearance of compressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disappearance of cosmetic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z-BMI or percentage overweight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-point discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of healthy items consumed for breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breakfast skipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer distress behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: greater coping behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increased cooperation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ca2+ uptake by platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ca2+ efflux from platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-training mean skill scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving ≥75% of protein requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight-adjusted energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women achieving vaginal delivery within 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: bevel deformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response to antidepressant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer cicatrisation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SCL depression mean item score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the vax-SPIRAL vaccine
Endpoint domain: Mortality/survival
Primary endpoint: Relative risk of becoming ill with leptospirosis
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Doubling dose increase in histamine EC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Doubling dose increase in PD20 histamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in HGR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WKT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Households with temephos observed in water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of abdominal pain/discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean improvement in visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants gaining ≥3 lines in VA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opiate positive urine drug screen (UDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total impression of speech quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PMBR (Post-Movement Beta Rhythm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRBD (Movement-Related Beta Desynchronization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean glucose for the 4-h after-meal period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SMBG frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: weekly mean pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hospitalization for suicide and self-harm
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of developing new-onset alcohol or substance use disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of psychiatric hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: CMAI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sympathetic nervous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parasympathetic nervous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patient compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Retinal Thickness (RT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awakening response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Risk of prolonged hypoglycemia
Endpoint domain: Mortality/survival
Primary endpoint: Initial complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Noninferiority of HA‐trehalose to HA for keratoconjunctivitis sicca assessed by Oxford grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good quality embryo rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: serum concentrations of apoA‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: concentrations of apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: apoB/apoA‐I ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to achieve Ramsay sedation score ≥ 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior movement at Point A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior movement at Points B and Pog
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma 15‐epi‐LXA(4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in swallowing behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved airway protection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter time to hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Risk of sensitization in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Laryngospasm
Endpoint domain: Adverse events/effects
Primary endpoint: Patient's overall satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of diet history measurement for energy and macronutrient intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of underreporting of energy intake
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of esophageal peristaltic contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Esophageal emptying of the solid bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom scores reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erythrocyte aggregation index (AI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythrocyte aggregation half time (T½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: plasma removed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PLT decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PRR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Persistence with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Association between Lp(a) levels and carotid atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative urinary UMEC excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 200-m fast-walk test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of CAC volume scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Refractive error measured by AR-360A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity correlation with refraction difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of troublesome postvoid urinary dribbling
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of gastric cancer development
Endpoint domain: Mortality/survival
Primary endpoint: GB volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: GB ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completion of HADS questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunoglobulin G geometric mean concentrations (GMCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent responders at ≥0.35 μg/mL postinfant series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidences of local reactions and systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum IGF‐1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of serum IGF‐1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Full biochemical control of acromegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Timely administration of the first dose of HepB vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to IO attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of adverse reactions related to transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients receiving adequate CKD management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior ROI cortical vBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: ischaemic events
Endpoint domain: Mortality/survival
Primary endpoint: Serum ionized and total calcium concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary cyclic adenosine monophosphate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of rhPTH(1‐84)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes